Kornimate/medical-research-clean huggingface dataset:
evaluation of preoperative nasoendoscopy to predict difficult intubation

Conditions: Difficult or Failed Intubation; Obesity, Morbid

Summary: despite the availability of different methods for airway assessment, unexpectedly difficult intubations occur at a frequency of up to 15%. a variety of pre-intubation clinical screening tests have been advocated to predict difficult laryngoscopy and airway but their usefulness is limited in obese patients. could awake invasive airway assessment be more predictive for difficult airways in obese patients? the use of nasendoscopy assessment for the airway could be a useful additional invasive tool to predict the difficult airway in obese

predictors of difficult laryngoscopy and intubation may be less useful or irrelevant when there is a plan for video laryngoscopes (vl) intraoperative. vl improves laryngeal view in most patients, their use achieves a high success rate for intubation of patients with predicted difficult intubation, and those who have failed direct laryngoscopy\[6\]. in a study of over 2000 (vl) video laryngoscopies intubations, mallampati's score did not correlate with failed intubation. the strongest predictor of failure was neck pathology, including the presence of a surgical scar, radiation changes, or mass. in another study, risk factors for difficult vl intubation after direct laryngoscopy were cormack-lehane grade 3 or 4 views with direct laryngoscopy, short sternothyroid distance, and high upper lip bite test score. obesity is a recognized risk factor for difficulty with airway management. an audit of major complications of airway management (nap4) from over three million anesthetics in the united kingdom found twice as many case reports of major complications in obese patients, especially in the morbidly obese. it is less clear whether obesity increases the risk of difficult laryngoscopy or intubation. some studies suggest that obesity is a risk factor for both difficult mask ventilation and difficult laryngoscopy, while other studies suggest that with proper positioning and preparation, ventilation and laryngoscopy are not difficult \[12,13\]. wilson's score is an important development in predictivity of airway difficulties, wilson's in his study (1988) attempted to deductively identify patients for whom intubation will be difficult. this study aims to demonstrate the use of preoperative awake fibreoptic examination

Eligibility criteria:
inclusion criteria: * adult patients between 18-60 years of age either male or female with (asa i, ii or iii ), scheduled for a bariatric procedure with a body mass index (bmi) greater than 35 k/m2, will be enrolled exclusion criteria: * patients on the tracheostomy tube * patients who are unable to give consent

Keywords: nasoendoscopy, obesity, difficult intubation
d-dimer prognostic marker of cerebral infarction after revascularization procedure

Conditions: Cerebral Infarction; Cerebral Infarction Recovery

Summary: cerebral infarction is the leading cause of acquired disability in adults. absence of biological marker used in current practice and identified as a prognostic factor for recovery. d-dimers are degradation products of stabilized fibrin translating an activation of coagulation whatever the cause. studies have shown that increased d-dimer levels in patients with mi is associated with a higher mortality rate, the link with post-intervention non-revascularization has been demonstrate. the purpose of this project is to search for a correlation between the level of d-dimer and the degree of recovery evaluated by the nihss score


Eligibility criteria:
inclusion criteria: * patients aged 18 to 65 * cerebral infarctions undergoing a revascularization procedure by thrombolysis and / or thrombectomy, at the amiens university hospital between january 2015 and december 2020. * patients having benefited from a d-dimer assay (during their stay) exclusion criteria: -

Keywords: cerebral infarction cerebral infarction recovery
cerebral venous sinus thrombosis: re-exploration of clinical assessment scales

Conditions: Cerebral Venous Sinus Thrombosis; CSF Pressure Increased; Papilledema

Summary: this is a single-center, retrospective, open-label study. this study is planned to investigate the accuracy of mrs and nihss, comparing with the accuracy of csf pressure and papilledema grade in assessing cerebral venous sinus thrombosis.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cvst by head mri, dsa or mrv onset of cvst within one month exclusion criteria: * unable to complete examinations unable to complete follow-ups

Keywords: cerebral venous sinus thrombosis csf pressure modified rankin scale papilledema nihss
consultations reason for genital, urinary or psychological humans in general practice

Conditions: Premature Ejaculation

Summary: many male patients complain about their ejaculation: 21-30% of men aged between 18 and 59 have admitted suffering from a decrease in, or loss of control of, their ejaculation. the quality of life of patients and their partners is impaired compared to men not suffering from premature ejaculation. economically, the impact of the disease are significant. in the year preceding the detection of premature ejaculation patients visit twice their physician. the majority of men interviewed anonymously, in their general practitioner's ( gp's) waiting room, considered it important to talk with their gp about their sexual concerns. almost half of them preferred that their gp initiate any discussions about sexuality. more than two thirds of the respondents would have liked their gp to signal his or her open-mindedness by directly addressing sexual topics during the consultation. in 2008 a qualitative study brought to the fore the strategies used by gps to initiate the discussion on premature ejaculation . gps who mentioned premature ejaculation with their patient described three attitude-related strategies and three investigative strategies.


Eligibility criteria:
inclusion criteria: * male patients overbetween 18 and 80 years old and * patients consulting for a sexual, urogenital or psychological reason according to interntational classification of primary care (icpc-2) will be included. exclusion criteria: * patients consulting for aanother reason for visiting thethan urogenital pattern, sexual or psychological * nonunderstanding of the french language * patients with psychiatric disorders affecting judgement * patient refusal to participate in the study

Keywords: premature ejaculation general practice sexual dysfunction
rare and undiagnosed disease research biorepository

Conditions: Undiagnosed Disease; Rare Diseases

Summary: this research study is being done to find markers and identify causes of rare and undiagnosed diseases by analyzing patient's dna (i.e., genetic material), rna, plasma, urine, tissues, or other samples that could be informative of symptoms. researchers are creating a biobank (library) of samples and information to learn more about treating rare and undiagnosed diseases.


Eligibility criteria:
inclusion criteria: * has mayo clinic or other medical health system id, or another unique identifier * able to provide informed consent must meet one of the following: * individual must have evidence of a rare disease or a suspected genetic disorder as determined by a provider or genetic counselor * biological family member of an enrolled individual exclusion criteria: * individuals who have situations that would limit compliance with the study requirements * institutionalized (i.e. federal medical prison)
safety and efficacy of arformoterol tartrate inhalation solution in subjects with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Bronchitis; Emphysema

Summary: to evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (copd).

this is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel group, outpatient, safety study to evaluate the long term safety of arformoterol in the treatment of subjects with copd. study participation will be over approximately 6 months. this study was previously posted by sepracor inc. in october 2009, sepracor inc. was acquired by dainippon sumitomo pharma., and in october 2010, sepracor inc's name was changed to sunovion pharmaceuticals inc.

Eligibility criteria:
key inclusion criteria: * male and female subjects must be at least 35 years old at the time of consent * subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic copd or are referred for diagnosis of non-asthmatic copd * subjects must have a \>=15 pack-year smoking history and a baseline breathlessness severity grade of \>=2 (modified medical research council \[mmrc\] dyspnea scale score) at visits 1 and 2 * female subjects \<=65 years of age must have a negative serum pregnancy test, females of childbearing potential must be using an acceptable method of birth control * subjects must be in general good health. key exclusion criteria: * subjects with a history of asthma, with the exception of asthma diagnosed in childhood * subjects with a blood eosinophil count \>5% of total white blood cell count * subjects have had a febrile illness within 72 hours (3 days) before screening visit 1 * subjects with a chest x-ray that suggests a diagnosis other than copd (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions)

Keywords: copd chronic bronchitis emphysema
the effect of video-based education on anxiety, pain and recovery quality in patients undergoing laparoscopic cholecystectomy.

Conditions: Laparoscopic Cholecystectomy

Summary: the reasons for anxiety before laparoscopic cholecystectomy include the operation of the surgery process, its therapeutic effect, lack of information about the postoperative period and lack of communication. the increase in the preoperative anxiety level in patients undergoing surgical intervention negatively affects the patients\&#39; sleep, recovery and quality of life, length of hospital stay is prolonged, cost increases in hospitals, and socioeconomic losses occur in individuals and institutions. therefore, this study will be conducted as a randomized controlled experimental study to determine the effect of video-based training given by an operating room nurse to patients undergoing laparoscopic cholecystectomy on preoperative anxiety, postoperative pain and recovery quality. considering possible sample loss, it was decided to include 72 patients, 36 in the intervention group and 36 in the control group. one of the patients included in both the intervention and control groups was excluded from the study because he was converted to open cholecystectomy during surgery and was taken to intensive care postoperatively. the study was completed with a total of 70 patients, 35 in the intervention group and 35 in the control group. patient information form, surgical anxiety scale, visual analogue scale (vas) and recovery quality scale-15 will be used to collect data.

a total of 2 patients, 1 patients in the experimental and 1 patients in the control groups, were excluded from the study because they were converted from laparoscopic surgery to open surgery.the study was completed with 70 patients (35 experimental and 35 control) who underwent laparoscopic cholecystectomy and met the inclusion criteria.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the research, * knows how to read, write and speak turkish, * patients who will undergo elective laparoscopic cholecystectomy in the general surgery service will be included. exclusion criteria: * have cognitive, auditory and psychological problems that may affect communication with researchers, * using psychiatric medication, * undergoing surgical intervention under emergency conditions, * subjected to spinal, epidural or local anesthesia during surge

Keywords: video-based education operating room nurse laparoscopic cholecystectomy
a united states study of the safety and tolerability of corlux for psychotic symptoms in psychotic major depression

Conditions: Major Depressive Disorder; Psychotic Disorders

Summary: corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. people who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. if corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. the purpose of this 56 day study is to learn the safety and effectiveness of corlux in patients who have been diagnosed with psychotic major depression (pmd).


Eligibility criteria:
inclusion criteria: individuals eligible for enrollment into this study are male and female adult patients who: * are 18 to 75 years of age * have a diagnosis of major depressive disorder with psychotic features (dsm-iv 296.24 or 296.34) * are able to provide written informed consent. exclusion criteria: individuals not eligible to be enrolled into the study are those who: * have a major medical problem * have previously participated in a corlux (c-1073, mifepristone) clinical trial * have a history of an allergic reaction to corlux (c-1073, mifepristone).

Keywords: pmd psychotic depression psychosis major depression depression psychotic major depression
effect of mra on cardiovascular disease in patients with hypertension and hyperaldosteronemia

Conditions: Hypertension; Hyperaldosteronaemia

Summary: elevated aldosterone causes moderate to severe increase in blood pressure, and leads to various target organ damage including cardiovascular ones. aldosterone has been considered one of the important risk factors for cardiovascular and cerebrovascular diseases. currently, the use of mineralocorticoid receptor antagonists(mra) has been proven to reduce blood pressure levels, but long-term prognostic data are lacking in hypertensive patients. therefore, the purpose of this clinical trial is to assess the effect of mra on cardiovascular disease in patients with hypertension and hyperaldosteronemia.

the trial will randomize about 7800 participants aged between 30 and 75 years with hypertension and hyperaldosteronemia(plasma aldosterone concentration \>12 ng/dl). all participants were randomly assigned to two different intervention groups. one group was treated with mineralocorticoid receptor antagonists(mras) (including spironolactone 20-60mg/ day, or eplerenone50-100mg/day, or finerenone 10-20mg/ day) in addition to the original antihypertensive drugs. one group was given the original antihypertensive drugs.

Eligibility criteria:
inclusion criteria: 1. age: 18-75 years old; 2. blood pressure ≥140/90 mmhg, or have taken antihypertensive drugs; 3. plasma aldosterone concentration\> 12ng/ dl; 4. serum potassium \< 4.8mmol/l; 5. signed the written informed consent. exclusion criteria: 1. sbp/dbp≥190/120mmhg, dbp\<60 mmhg; 2. known secondary cause of hypertension, including pheochromocytoma, primary aldosteronism (adrenal tumor \> 1cm), cushing's syndrome, renal artery stenosis, renin tumor, connotation of aorta, etc.; 3. history of ischemic or hemorrhagic stroke within the last 3 months (not lacunar infarction and transient ischemic attack \[tia\]). 4. history of hospitalization for myocardial infarction or unstable angina, or coronary revascularization (pci or cabg) within the last 3 months. 5. history of aortic dissection/dissection aneurysm rupture. 6. history of nyha grade iii-iv heart failure or hospitalization aggravated chronic heart failure upon admission within the last 3 months. 7. a history of persistent atrial fibrillation, atrial flutter, or other severe arrhythmias on admission (including sinus delay, diseased sinus, high atrioventricular block, frequent ventricular morning, etc.). 8. severe liver disease or liver dysfunction: ast, alt, or alp \> 5uln (5 times the upper limit of normal), or bil \> 3uln (3 times the upper limit of normal). 9. end-stage renal disease (esrd) on dialysis, or estimated glomerular filtration rate (egfr) \ 2.5 mg/dl \[\>221 umol/l\]; 10. patients with serious physical diseases such as malignant tumors and autoimmune diseases. 11. severe cognitive or mental impairment. 12. pregnant and lactating women. 13. those who have contraindications or allergies to mras. 14. patients with hypoadrenocortical function. 15. participating in other clinical trials.
the implementation of a post-operative communication app to improve pain control and opioid use

Conditions: Acute Pain

Summary: digital communication tools are becoming ubiquitous in healthcare, though their impact on patient/provider communication, healthcare utilization, and outcomes remains poorly established. m health fairview (mhfv) in collaboration with the center for learning health system sciences (clhss) rapid eval team will be evaluating one such communication application: opy, which leverages the epic-care companion functionality to remove barriers in communicating with the patient's care team. this project will evaluate the effectiveness of a digital, post-operative patient engagement tool (epic-care companion made available through mychart), opy, which has the goal of preventing patients from becoming addicted to opioids or to suffer from opioid misuse or diversion. in the proposed pragmatic trial, standard care with education available in mychart and the patient after visit summary will be augmented by opy. opy is available to patients starting the same day they go home from surgery with a new opioid prescription. opy provides a daily interactive experience that collects patient pain and side-effect information, provides advice for pain management, and uses behavioral "nudges" to encourage timely weaning and responsible disposal of opioid medications. the primary goal of this project is to evaluate the effect of two versions of opy on measures of opiate use relative to the standard of care in a pragmatic randomized controlled trial.


Eligibility criteria:
inclusion criteria: * surgery at the m health fairview clinics and surgery center - maple grove (maple grove) or m health fairview clinics and surgery center - minneapolis (csc) ▪ currently, only outpatient surgeries are performed at csc and maple grove * active opioid prescription (prescribed between 30 days prior to surgery, until day of surgery) * patient class (outpatient or same day surgery) * never previously randomized or exposed to opy exclusion criteria: * age \< 18 * chronic opiate use defined as: * patients aged 18 and older and * 3 or more opioid dispensing events, in the last 12 months with at least 1 of these events in the last 6 months. * any long acting opioid prescription in the last 6 months * interpreter needed - yes selected (ept840) * patient has a health proxy (legal guardian) designated in epic * patients who have opted out of clinical research * patients with an active palliative care referral
study on intraocular structural parameters and surgical effect before and after the onset of malignant glaucoma

Conditions: Glaucoma; Malignant Glaucoma

Summary: in this retrospective observational study, we collected intraocular structure parameters of malignant glaucoma and primary angle closure glaucoma. anterior chamber depth (acd) and width (acw), lens vault (lv), ciliary process-ciliary process distance(ccd), trabecular-ciliary processes distance (tcpd), ciliary body max thickness (cbmt), peripheral iris thickness (pit), trabecular ciliary process angle (tcpa), and anterior vault (av), were measured by ultrasound biomicroscopy. other parameters measured by a-scan ultrasonography and optical coherence tomography. to analyze the high risk factors and the possible pathogenesis of the disease and discuss the long-term effect of different treatment methods.

outcome measures: anterior chamber depth (acd) and width (acw), lens vault (lv), ciliary process-ciliary process distance(ccd), trabecular-ciliary processes distance (tcpd), ciliary body max thickness (cbmt), peripheral iris thickness (pit), trabecular ciliary process angle (tcpa), and anterior vault (av), were measured by ultrasound biomicroscopy. other parameters measured by a-scan ultrasonography and optical coherence tomography.

Eligibility criteria:
inclusion criteria: (1) history of operation, (2) diagnosis of mg, and (3) eyes with clear optical media. exclusion criteria:(1)hypertension or diabetes and (2) diagnosis of ocular fundus diseases.

Keywords: malignant glaucoma biometric measurements
post-market evaluation of odysight app to monitor near visual acuity at home (til002)

Conditions: Visual Impairment

Summary: odysight is a mobile application allowing self-testing of visual parameters including near visual acuity and communication of the data to an online dashboard to patient's doctors. til-002 post-market clinical trial objective is to evaluate the near visual acuity at home, measured with odysight application in comparison to the standardized methods. the clinical trial is intended to prove that odysight can provide relevant data and participate in the remote monitoring of subject vision.


Eligibility criteria:
inclusion criteria: general inclusion criteria: 1. age ≥ 18 years, all genders 2. affiliated to or beneficiary of the french health care system 3. signed/written informed consent 4. already user of odysight on a compatible smartphone/tablet 5. patients willing and able to comply with all study and follow-up procedure ophthalmic inclusion criterion: 6. baseline binocular visual acuity with habitual correction ≥ 20/63 (3/10) and with at least an eye ≥ 20/200 (1/10). exclusion criteria: general exclusion criteria: 1. any pathology that is considered by the investigator as capable of affecting the quality of the main evaluation criteria. 2. any planned surgery likely to modify patient refraction during the study (cataract surgery for example) 3. subject not considered by the investigator or designee to correctly use odysight modules 4. subject unable to recognize alphabet letters or unable to correctly distinguish body laterality 5. not french speaking patient 6. epileptic users

Keywords: visual acuity digital therapeutics medical software etdrs macular edema age-related macular degeneration
the aspect study - asian paclitaxel-eluting stent clinical trial

Conditions: Coronary Artery Disease

Summary: the aspect study is an asian multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the cook incorporated paclitaxel eluting supra g coronary stent to reduce restenosis in the coronary artery.


Eligibility criteria:
inclusion criteria: * patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery. * patient must be an acceptable candidate for coronary artery bypass surgery. * patient must have given signed informed consent. * patient agrees to return at one month for an office visit to assess cardiovascular status and at 4-6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram. exclusion criteria: * patient is less than 18 years old. * patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. * the patient is simultaneously participating in another investigative interventional cardiovascular device or drug study. * patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye that. * patient is pregnant. * patient has other medical condition that may cause the patient to be non-compliant with the protocol, confound the results or is associated with limited life expectancy.

Keywords: coronary artery stenosis drug eluting stent stent